Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4965—Non-condensed pyrazines
  • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/10—Spiro-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems
  • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Definitions

• the present invention relates to compounds inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof.
• DDR inhibitors Discoidin Domain Receptors
• the compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
• DDRs Discoidin Domain Receptors
• RTKs transmembrane receptor tyrosine kinase
• DDRs are unique receptors among the other members of the RTK superfamily, in that DDRs are activated by collagen whereas other members of the RTK superfamily are typically activated by soluble peptide-like growth factors (see Vogel, W. (1997) Mol. Cell 1, 13-23; Shrivastava A. Mol Cell. 1997; 1 :25-34.). Moreover, DDRs are unusual RTKs also because they form ligand-independent stable dimers that are non-covalently linked (seeNoordeen, N. A.(2006) J. Biol. Chem. 281, 22744-22751; Mihai C. JMol Biol. 2009; 385:432-445).
• the DDR1 subfamily is composed of five membrane-anchored isoforms, and the DDR2 subfamily is represented by a single protein.
• the five DDR1 isoforms all have in common the extracellular and transmembrane domains but differ in the cytoplasmic region (see Valiathan, R. R. (2012) Cancer Metastasis Rev. 31, 295-321; Alves, F. (2001) FASEB J. 15, 1321-1323).
• DDR receptor family has been found involved in a series of fibrotic diseases, such as pulmonary fibrosis, and in particular idiopathic pulmonary fibrosis (IDF).
• pulmonary fibrosis and in particular idiopathic pulmonary fibrosis (IDF).
• IDF idiopathic pulmonary fibrosis
• DDR1 expression is a prerequisite for the development of lung inflammation and fibrosis.
• DDR2 deficiency or downregulation reduces bleomycin-induced lung fibrosis (see Zhao H, Bian H, Bu X, Zhang S, Zhang P, Yu J, et al Mol Ther 2016; 24: 1734-1744).
• Zhao et al demonstrated that DDR2 plays a critical role in the induction of fibrosis and angiogenesis in the lung, in particular that DDR2 synergizes with transforming growth factor (TGF)-P to induce myofibroblast differentiation.
• TGF transforming growth factor
• DDR1 or DDR2 antagonists Some compounds have been described in the literature as DDR1 or DDR2 antagonists.
• antagonizing the DDR receptors may be useful for the treatment of fibrosis and diseases, disorders and conditions that result from fibrosis. Even more, antagonizing both receptors DDR1 and DDR2 may be particularly efficacious in the treatment of the above-mentioned diseases, disorders and conditions.
• the present invention relates to a compound of formula (I) wherein
• Y is absent or is -C(O)-;
• Ri is -(Ci-Ce)alkylene-NRARB or hydrogen
• Rj is -(Ci-C4)alkyl
• A is selected from the group consisting of Al, A2, A3
• R2 is H or selected from the group consisting of halogen, cyano, -NRARB, -C(O)NRARB, -C(O)NR c -(Ci-C6)alkylene-NR A RB, -C(O)NR c -(Ci-C 6 )alkylene-ORA, -NR A C(O)R B , - ORA, -NR c -(Ci-C 6 )alkylene-ORA, -NR c -(Ci-C6)alkylene-NR A RB, -C(O)NRA- heterocycloalkyl, heterocycloalkyl, -NRA-heteroaryl, -(Ci-C6)alkylene-heterocycloalkyl, -(Ci-Ce)alkylene-ORA, -O-(Ci-Ce)alkylene-NRARB, -O-(Ci-Ce)alkylene-
• RA, RB and Rc are independently -(Ci-Ce)alkyl or hydrogen; or RA and RB taken together with the nitrogen they are attached to may form a heterocycloalkyl; and wherein each heterocycloalkyl or heteroaryl of R2 is substituted by one or more, preferably 1 to 3, substituents independently selected from the group consisting of hydrogen, halogen, -(Ci-Ce)alkyl, -(Ci-Ce)haloalkyl, -(Ci-Ce)alkylene-ORA, -ORA, -O- (Ci-Ce)alkylene-NRARB and -O-(Ci-Ce)alkylene-ORA; and pharmaceutically acceptable salts thereof.
• the invention refers to a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I) and pharmaceutically acceptable salts thereof in a mixture with one or more pharmaceutically acceptable carrier or excipient.
• the invention refers to a compound of formula (I) and pharmaceutically acceptable salts or to a pharmaceutical composition comprising a compound of formula (I) and pharmaceutically acceptable salts thereof for use as a medicament.
• the invention refers to a compound of formula (I) and pharmaceutically acceptable salts thereof or to a pharmaceutical composition comprising a compound of formula (I) and pharmaceutically acceptable salts thereof for use in preventing and/or treating a disease, disorder or condition associated with dysregulation of DDR.
• the invention refers to a compound of formula (I) and pharmaceutically acceptable salts thereof or to a pharmaceutical composition comprising a compound of formula (I) and pharmaceutically acceptable salts thereof for use in the prevention and/or treatment of fibrosis and/or diseases, disorders, or conditions that involve fibrosis.
• the invention refers to a compound of formula (I) and pharmaceutically acceptable salts thereof or to a pharmaceutical composition comprising a compound of formula (I) and pharmaceutically acceptable salts thereof for use in the prevention and/or treatment of idiopathic pulmonary fibrosis (IPF).
• IPF idiopathic pulmonary fibrosis
• the compounds of formula (I) of the present invention are intended to include stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof.
• the compounds of formula (I) of the present invention are intended to include the compounds of formula (I)’, (la), (la)’, (laa), (laa)’, (lab), (lab)’, (lb), (lb)’, (Ic), (Ic)’, (lea), (lea)’, (Id), (Id)’ and (le).
• pharmaceutically acceptable salts refers to derivatives of compounds of formula (I) wherein the parent compound is suitably modified by converting any of the free acid or basic group, if present, into the corresponding addition salt with any base or acid conventionally intended as being pharmaceutically acceptable.
• Suitable examples of said salts may thus include mineral or organic acid addition salts of basic residues such as amino groups, as well as mineral or organic basic addition salts of acid residues such as carboxylic groups.
• Cations of inorganic bases which can be suitably used to prepare salts comprise ions of alkali or alkaline earth metals, such as potassium, sodium, calcium or magnesium.
• the salts obtained by reacting the main compound, functioning as a base, with an inorganic or organic acid comprise, for example, salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, acetic acid, oxalic acid, maleic acid, fumaric acid, succinic acid and citric acid.
• stereoisomer refers to isomers of identical constitution that differ in the arrangement of their atoms in space. Enantiomers and diastereomers are examples of stereoisomers.
• enantiomer refers to one of a pair of molecular species that are mirror images of each other and are not superimposable.
• racemate or “racemic mixture” refers to a composition composed of equimolar quantities of two enantiomeric species, wherein the composition is devoid of optical activity.
• halogen or “halogen atoms” or “halo” as used herein includes fluorine, chlorine, bromine and iodine atom.
• (C x -C y )alkyl refers to a straight or branched chain alkyl group having from x to y carbon atoms.
• x is 1 and y is 4, for example, the term comprises methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.
• (C x -C y )haloalkyl refers to a straight or branched chain alkyl group having from x to y carbon atoms, comprising at least one halogen substituent.
• x is 1 and y is 6, for example, the term comprises, for instance, CF3, CHF2 and C(CH3)2CF3.
• (C x -C y )alkylene refers to a bivalent saturated aliphatic chain derived from an alkane, having from x to y carbon atoms, by removal of two hydrogen atoms from different carbon atoms; e.g. methylenyl.
• heterocycloalkyl refers to a saturated or partly unsaturated mono-, bi- or spirocyclic ring system of 3 to 12 ring atoms comprising one or more heteroatoms selected from N, S or O.
• An example of heterocycloalkyl is piperazinyl.
• spirocyclic ring system refers to a saturated or partly unsaturated bicyclic ring system of 5 to 12 ring atoms, comprising one or more, for instance 1 to 3, heteroatoms selected from N, S and O, wherein the two rings have only one common carbon atom.
• spiro-cyclic ring systems examples include spiro[3.5]nonanyl, spiro[2.3]hexanyl, spiro[2.4]heptanyl, 2-azaspiro[3.3]heptanyl, 7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.3]heptanyl, 2-oxa-6-azaspiro[3.4]octanyl and 2- azaspiro [3.5 ] nonany 1.
• heteroaryl refers to a mono- or bi-cyclic aromatic ring system, comprising a number of ring atoms from 5 to 10 and comprising from 1 to 4, or 1 to 3, or 1 to 2, heteroatoms independently selected from N, S and O, and includes groups having two such monocyclic rings, or one such monocyclic ring and one monocyclic aryl ring, such as a phenyl ring, which are fused through a common bond or linked by a single bond.
• the heteroaryl ring system comprises pyrazolyl, furanyl, tiophenyl, oxazolyl, isoxazolyl, isothiazolyl, thiazolyl, imidazolyl, benzofuranyl, lH-benzo[d]imidazolyl, IH-indazolyl, benzothiophenyl, benzo[c]thiophenyl, quinazolinyl, pteridinyl, lH-pyrazolo[5,l- c][l,2,4]triazolyl, pyrrolizinyl, indolizinyl, benzothiazolyl, pyrazolo[5,l-b]thiazolyl, 1H- imidazo[l,2-b]pyrazolyl, lH-pyrazolo[3,4-b]pyridinyl, l,6-dihydropyrrolo[2,3- b]pyrrolyl, l,4-
• physiologically acceptable anions may be present, selected among chloride, bromide, iodide, trifluoroacetate, formate, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, p-toluenesulfonate, pamoate and naphthalene disulfonate.
• corresponding physiological cations may be present as well, for instance including alkaline or alkaline earth metal ions.
• Ki indicates the dissociation constant for the enzyme-inhibitor complex, expressed in molar units. It is an indicator of the binding affinity between inhibitor and DDR1 or DDR2 receptors.
• the present invention refers to a series of compounds represented by the general formula (I) as herein below described in details, which are endowed with an inhhibitory activity on receptors DDR1 and DDR2.
• Antagonizing receptors DDR1 and DDR2 can be particularly effective in the treatment of those diseases where the DDR receptors play a role, such as fibrosis and any other disease, disorder and condition related to fibrosis.
• the compounds of formula (I) of the present invention are able to act as inhibitors of both DDR1 and DDR2 receptors in a substantive and effective way.
• Table 5 below shows that for the compounds of the present invention, the inhibitory activity against either DDR1 and DDR2 receptors is lower than 60 nM in the binding (expressed as Ki). This confirms that the compounds of formula (I) are able to inhibit the two isoforms of DDR receptor mainly involved in fibrosis and diseases resulting from fibrosis. Accordingly, the compounds of formula (I) can be used in the treatment of fibrosis, in particular pulmonary fibrosis, when DDR1 and DDR2 are involved.
• comparative compounds section in particular in Table 6, conversely to comparative Compound Cl, characterized by having an aziridinyl in place of a pyrrolidinyl ring, the presence of a pyrrolidinyl ring in the compounds of the present invention unexpectedly and remarkably determines a relevant increase in the inhibitory activity on the DDR1 and DDR2 receptors.
• the compounds of the present invention are endowed by a very high potency and could be administered in human at a lower dosage respect to the compounds of the prior art, thus reducing the adverse events that typically occur administering higher dosages of drug.
• the compounds of the present invention are also characterized by being selective inhibitors of DDR1 and DDR2 receptors with respect to other human protein kinases, by a good inhalatory profile, that permits to act effectively on the lung compartment and have, at the same time, a low metabolic stability, that allows to minimize the drawbacks associated with the systemic exposure, such as safety and tolerability issues.
• the compounds of the present invention may be particularly appreciated when looking at suitable and efficacious compounds useful for the treatment of fibrosis, in particular idiopathic pulmonary fibrosis, administered by the inhalation route and characterized by a good inhalatory profile, that corresponds to a good activity on the lung, a good lung retention and a low metabolic stability, that minimizes the systemic exposure and correlated safety issues.
• the present invention relates to a compound of general formula
• Y is absent or is -C(O)-;
• Ri is -(Ci-Ce)alkylene-NRARB or hydrogen
• Rj is -(Ci-C4)alkyl, preferably methyl
• A is selected from the group consisting of Al, A2, A3 and bicyclic heteroaryl B, wherein * indicates the point of attachment to Y and B is substituted by R2; wherein
• R2 is H or selected from the group consisting of halogen, cyano, -NRARB, -C(O)NRARB, -C(O)NR c -(Ci-C6)alkylene-NR A RB, -C(O)NR c -(Ci-C 6 )alkylene-ORA, -NR A C(O)R B , - ORA, -NR c -(Ci-C 6 )alkylene-ORA, -NR c -(Ci-C6)alkylene-NR A RB, -C(O)NRA- heterocycloalkyl, heterocycloalkyl, -NRA-heteroaryl, -(Ci-C6)alkylene-heterocycloalkyl, -(Ci-Ce)alkylene-ORA, -O-(Ci-Ce)alkylene-NRARB, -O-(Ci-Ce)alkylene-
• RA, RB and Rc are independently -(Ci-Ce)alkyl or hydrogen; or RA and RB taken together with the nitrogen they are attached to may form a heterocycloalkyl; and wherein each heterocycloalkyl or heteroaryl of R2 is substituted by one or more, preferably 1 to 3, substituents independently selected from the group consisting of hydrogen, halogen, -(Ci-Ce)alkyl, -(Ci-Ce)haloalkyl, -(Ci-Ce)alkylene-ORA, -ORA, -O- (Ci-Ce)alkylene-NRARB and -O-(Ci-C6)alkylene-ORA; and pharmaceutically acceptable salts thereof.
• variable moieties Y, A, Ri, R2, R3, RA, RB and Rc of the compound of formula (I) of the invention have to be intended as alternatives and may be combined with each other in embodiments which are included in the scope of the invention.
• halogens as such and in -(Ci-Ce)haloalkyl substituents, are fluorine and bromine, wherein fluorine is more preferred.
• -(Ci-Ce)alkylene- chains are -(Ci- C3)alkylene- chains.
• -(Ci-Ce)alkyl substituents are -(Ci- C4)alkyl substituents.
• Ri and R2 are single substituents of the CFi-substituted phenyl and of A, respectively, wherein Ri and R2 can be attached to any available position.
• Preferred positions for substituent Ri is para- or meta- to the -NH-C(O)- substituent.
• Preferred positions for substituent R2 are outlined in the embodiments of the invention as described further below.
• the present invention relates to a compound of general formula (I) wherein Ri is hydrogen and Rj is methyl, represented by formula (I)’ wherein
• Y is absent or is -C(O)-;
• A is selected from the group consisting of Al, A2 and A3 wherein * indicates the point of attachment to Y; and wherein
• R2 is H or selected from the group consisting of halogen atoms, cyano, -C(O)NH2, -
• ORA -NHC(O)RB, -O-(Ci-C 6 )alkyl, -NH-(Ci-C 6 )alkylene-OR A , -C(O)NH- heterocycloalkyl, heterocycloalkyl, -(Ci-C6)alkylene-heterocycloalkyl and -O-(Ci- C6)alkylene-heterocycloalkyl, wherein each of said heterocycloalkyl is optionally substituted by one or more -(Ci-Ce)alkyl;
• RA is -(Ci-Ce)alkyl
• RB is -(Ci-Ce)alkyl; and pharmaceutically acceptable salts thereof.
• the present invention relates to a compound of formula (I) wherein Y is absent.
• the present invention relates to a compound of formula (I) wherein Y is absent and A is Al
• the present invention relates to a compound of formula (la) wherein Ri is hydrogen and Rj is methyl, represented by formula (la)’
• R2 is H or selected from the group consisting of halogen atoms, cyano, -C(O)NH2, - C(O)NH-(Ci-C 6 )alkyl, -C(O)NH-(Ci-C 6 )alkylene-NR A RB, -C(O)NH-(Ci-C 6 )alkylene- ORA, -NHC(O)RB-, -O-(Ci-C 6 )alkyl, -NH-(Ci-C 6 )alkylene-OR A , -C(O)NH- heterocycloalkyl, heterocycloalkyl, -(Ci-C6)alkylene-heterocycloalkyl and -O-(Ci- C6)alkylene-heterocycloalkyl, wherein each of said heterocycloalkyl is optionally substituted by one or more (Ci-Ce)alkyl;
• RA is -(Ci-Ce)alkyl
• RB is -(Ci-Ce)alkyl; and pharmaceutically acceptable salts thereof.
• the present invention relates to a compound of general formula (I) wherein Y is absent and A is Ala represented by formula (laa)
• the present invention relates to a compound of formula (laa) wherein Ri is hydrogen and Rj is methyl, represented by formula (laa)’ wherein
• R2 is H or selected from the group consisting of halogen atoms, cyano, -C(O)NH2, - C(O)NH-(Ci-C 6 )alkyl, -C(O)NH-(Ci-C 6 )alkylene-NR A RB, -C(O)NH-(Ci-C 6 )alkylene- ORA, -NHC(O)RB, -O-(Ci-C 6 )alkyl, -NH-(Ci-C 6 )alkylene-OR A , -C(O)NH- heterocycloalkyl, heterocycloalkyl, -(Ci-C6)alkylene-heterocycloalkyl and -O-(Ci- C6)alkylene-heterocycloalkyl, wherein each of said heterocycloalkyl is optionally substituted by one or more (Ci-Ce)alkyl;
• RA is -(Ci-Ce)alkyl
• RB is -(Ci-Ce)alkyl; and pharmaceutically acceptable salts thereof.
• the present invention refers to a compound of formula (laa) or (laa)’, wherein R2 is H or is selected from the group consisting of methoxy, cyano, bromo, 2-morpholinoethoxy, (4-methylpiperazin-l-yl)ethoxy, morpholinyl, 2-(dimethylamino)ethylcarbamoyl, N-methylcarbamoyl, carbamoyl, morpholinomethyl and 4-methylpiperazin-l-yl.
• R2 is H or is selected from the group consisting of 2-(dimethylamino)ethoxy, 2-methoxy ethylcarbamoyl, acetamido and 1 -methyl - 1 H-3 -py razoly 1.
• the invention refers to at least one of the compounds of Formula (laa) listed in Table 1 below and pharmaceutically acceptable salts thereof. These compounds are particularly active on receptors DDR1 and DDR2, as shown in Table 5.
• the present invention relates to a compound of general formula (I) wherein Y is absent and A is Alb
• the present invention relates to a compound of formula (lab) wherein Ri is hydrogen and Rj is methyl, represented by formula (lab)’ (lab)’ wherein
• R2 is H or selected from the group consisting of halogen atoms, cyano, -C(O)NH2, - C(O)NH-(Ci-C 6 )alkyl, -C(O)NH-(Ci-C 6 )alkylene-NR A RB, -C(O)NH-(Ci-C 6 )alkylene- ORA, -NHC(O)RB, -O-(Ci-C 6 )alkyl, -NH-(Ci-C 6 )alkylene-OR A , -C(O)NH- heterocycloalkyl, heterocycloalkyl, -(Ci-C6)alkylene-heterocycloalkyl and -O-(Ci- C6)alkylene-heterocycloalkyl, wherein each of said heterocycloalkyl is optionally substituted by one or more (Ci-Ce)alkyl;
• RA is -(Ci-Ce)alkyl
• RB is -(Ci-Ce)alkyl; and pharmaceutically acceptable salts thereof.
• the invention refers to at least one of the compounds of Formula (lab) listed in Table 1 ’ below and pharmaceutically acceptable salts thereof. These compounds are particularly active on receptors DDR1 and DDR2, as shown in Table 5.
• the present invention refers to a compound of formula (I) wherein Y is -C(O)- and A is Al
• the present invention relates to a compound of formula (lb) wherein Ri is hydrogen and Rj is methyl, represented by formula (lb)’
• R2 is H or selected from the group consisting of halogen atoms, cyano, -C(O)NH2, - C(O)NH-(Ci-C 6 )alkyl, -C(O)NH-(Ci-C 6 )alkylene-NR A R B , -C(O)NH-(Ci-C 6 )alkylene- ORA, -NHC(O)RB, -O-(Ci-C 6 )alkyl, -NH-(Ci-C 6 )alkylene-OR A , -C(O)NH- heterocycloalkyl, heterocycloalkyl, -(Ci-C6)alkylene-heterocycloalkyl and -O-(Ci- C6)alkylene-heterocycloalkyl, wherein each of said heterocycloalkyl is optionally substituted by one or more -(Ci-Ce)alkyl;
• RA is -(Ci-Ce)alkyl
• RB is -(Ci-Ce)alkyl
• pharmaceutically acceptable salts thereof
• the invention refers to a compound of Formula (lb) listed in Table 2 below and pharmaceutically acceptable salts thereof. This compound is particularly active on receptors DDR1 and DDR2, as shown in Table 5.
• Table 2 List of compounds of Formula (lb)
• the present invention refers to a compound of formula (I) wherein Y is absent and A is A2 represented by formula (Ic)
• the present invention relates to a compound of formula (Ic) wherein Ri is hydrogen and Rj is methyl, represented by formula (Ic)’ (IC)’ wherein
• R2 is H or selected from the group consisting of halogen atoms, cyano, -C(O)NH2, -
• ORA -NHC(O)RB, -O-(Ci-C 6 )alkyl, -NH-(Ci-C 6 )alkylene-OR A , -C(O)NH- heterocycloalkyl, heterocycloalkyl, -(Ci-C6)alkylene-heterocycloalkyl and -O-(Ci- C6)alkylene-heterocycloalkyl, wherein each of said heterocycloalkyl is optionally substituted by one or more -(Ci-Ce)alkyl;
• RA is -(Ci-Ce)alkyl
• RB is -(Ci-Ce)alkyl; and pharmaceutically acceptable salts thereof.
• the present invention refers to a compound of formula (Ic) wherein A is Ala
• the present invention relates to a compound of formula (lea) wherein Ri is hydrogen and Rj is methyl, represented by formula (lea)’
• R2 is H or selected from the group consisting of halogen atoms, cyano, -C(O)NH2, - C(O)NH-(Ci-C 6 )alkyl, -C(O)NH-(Ci-C 6 )alkylene-NR A R B , -C(O)NH-(Ci-C 6 )alkylene- ORA, -NHC(O)RB, -O-(Ci-C 6 )alkyl, -NH-(Ci-C 6 )alkylene-OR A , -C(O)NH- heterocycloalkyl, heterocycloalkyl, -(Ci-C6)alkylene-heterocycloalkyl and -O-(Ci- C6)alkylene-heterocycloalkyl, wherein each of said heterocycloalkyl is optionally substituted by one or more -(Ci-Ce)alkyl;
• RA is -(Ci-Ce)alkyl
• RB is -(Ci-Ce)alkyl; and pharmaceutically acceptable salts thereof.
• the present invention refers to a compound of formula (lea) or (lea)’, wherein R2 is H, N-methylcarbamoyl, carbamoyl, cyano or acetamido.
• the invention refers to at least one of the compounds of Formula (lea) listed in Table 3 below and pharmaceutically acceptable salts thereof. These compounds are particularly active on receptors DDR1 and DDR2, as shown in Table 5.
• Table 3 List of compounds of Formula (lea)
• the present invention refers to a compound of formula (I) wherein Y is absent and A is A3
• the present invention relates to a compound of formula (Id) wherein Ri is hydrogen and Rj is methyl, represented by formula (Id)’
• R2 is H or selected from the group consisting of halogen atoms, cyano, -C(O)NH2, - C(O)NH-(Ci-C 6 )alkyl, -C(O)NH-(Ci-C 6 )alkylene-NR A RB, -C(O)NH-(Ci-C 6 )alkylene- ORA, -NHC(O)RB, -O-(Ci-C 6 )alkyl, -NH-(Ci-C 6 )alkylene-OR A , -C(O)NH- heterocycloalkyl, heterocycloalkyl, -(Ci-C6)alkylene-heterocycloalkyl and -O-(Ci- C6)alkylene-heterocycloalkyl, wherein each of said heterocycloalkyl is optionally substituted by one or more -(Ci-Ce)alkyl;
• RA is -(Ci-Ce)alkyl
• RB is -(Ci-Ce)alkyl; and pharmaceutically acceptable salts thereof.
• the invention refers to at least one of the compounds of Formula (Id) listed in Table 4 below and pharmaceutically acceptable salts thereof. These compounds are particularly active on receptors DDR1 and DDR2, as shown in Table 5.
• the present invention refers to a compound of formula (I) wherein Y is absent and A is bicyclic heteroaryl substituted by R2, as defined above, referred to as a compound of formula (le).
• the invention refers to at least one of the compounds of Formula (le) listed in Table 4a below and pharmaceutically acceptable salts thereof. These compounds are particularly active on receptors DDR1 and DDR2, as shown in Table 5.
• the compounds of the invention can be prepared from readily available starting materials using the following general methods and procedures or by using slightly modified processes readily available to those of ordinary skill in the art. Although a particular embodiment of the present invention may be shown or described herein, those skilled in the art will recognize that all embodiments or aspects of the present invention can be obtained using the methods described herein or by using other known methods, reagents and starting materials. When typical or preferred process conditions (i.e. reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. While the optimal reaction conditions may vary depending on the particular reactants or solvent used, such conditions can be readily determined by those skilled in the art by routine optimization procedures. Thus, processes described below should not be viewed as limiting the scope of the synthetic methods available for the preparation of the compounds of the invention.
• PG protective groups
• compounds of formula (I) may be prepared as described in Scheme 1, starting from commercially available compound (II).
• a compound of formula (IV) or (IV)’ can be prepared from a compound of formula (II) or (II)’, respectively, by converting it into the acyl chloride (III) or (III)’ using oxalyl chloride or thionyl chloride in a suitable solvent such as DMF or DCM, and performing subsequently an amide coupling with aryl amine (XI) or (XI)’ using a suitable base, such as DIPEA, in a suitable solvent, such as DCM, at RT.
• a compound of formula (IV) or (IV)’ may be prepared by following a one-step synthesis starting from a compound of formula (II) or (II)’, under suitable amide coupling reaction conditions.
• a compound of formula (II) or (II)’ and aryl amine (XI) or (XI)’ may be reacted in the presence of an activating agent, such as HATU or TBTU, with an organic base, such as DIPEA or TEA, in a suitable organic solvent, such as DCM or DMF, and at a temperature generally around RT for a time ranging from a few hours to overnight.
• an activating agent such as HATU or TBTU
• an organic base such as DIPEA or TEA
• a suitable organic solvent such as DCM or DMF
• a compound of formula (V) or (V)’ may be obtained from a compound of formula (IV) or (IV)’ through a palladium-catalyzed cross-coupling on the leaving group X, wherein X can be bromide or iodide.
• reaction may be carried out by reacting a compound of formula (IV) or (IV)’ with potassium trifluoro(vinyl)borate following the classical Suzuki protocol, in a suitable organic solvent, such as dioxane or THF, in the presence of an inorganic base, such as K2PO4 or CS2CO3, with an appropriate palladium catalytic system, such as Pd2(dppf)C12 or another palladium source/phosphine- based ligand, at high temperature (around 100 °C) for a few hours.
• a suitable organic solvent such as dioxane or THF
• an inorganic base such as K2PO4 or CS2CO3
• an appropriate palladium catalytic system such as Pd2(dppf)C12 or another palladium source/phosphine- based ligand
• 1,3-dipolar cycloaddition may be carried out reacting the a,B-unsaturated compound of formula (V) or (V)’ with a 1,3-dipole or a suitable precursor, such as an azomethine ylide, for example N-benzyl-1 -methoxy -N-((trimethylsilyl)methyl) methanamine, under acid catalysis, such as TFA, in a solvent such as dioxane.
• a suitable precursor such as an azomethine ylide, for example N-benzyl-1 -methoxy -N-((trimethylsilyl)methyl) methanamine
• the compound of formula (VI) or (VI)’ can be converted into the debenzylated compound of formula (VII) or (VII)’ by reduction under hydrogen atmosphere, typically 7-10 bar, in presence of a suitable catalyst such as Pd/C in a suitable solvent, such as, but not limited to, EtOH or MeOH at a temperature ranging from RT to 60 °C, for few hours.
• a suitable catalyst such as Pd/C
• a suitable solvent such as, but not limited to, EtOH or MeOH at a temperature ranging from RT to 60 °C, for few hours.
• a compound of formula (I) or (I)’, wherein Y is -C(O)- may be prepared with a one-step synthesis by starting from a compound of formula (VII) or (VII)’ and a carboxylic acid compound of formula (VIII) or (VIII)’, under suitable amide coupling reaction conditions in the presence of an activating agent, such as HATU or TBTU, with an organic base, such as DIPEA or TEA, in a suitable organic solvent, such as DCM or DMF, and at a temperature generally around RT for a time ranging from a few hours to overnight.
• an activating agent such as HATU or TBTU
• an organic base such as DIPEA or TEA
• a suitable organic solvent such as DCM or DMF
• a compound of formula (VII) or (VII)’ may be converted into a compound of formula (I) or (I)’, wherein Y is absent, by performing a Buchwald crosscoupling reaction, using a bromide compound of formula (X) or (X)’, in a suitable organic solvent, such as dioxane or toluene or DMA, in the presence of an inorganic base, such as K2PO4 or CS2CO3, with a suitable palladium catalytic system such as Pd(dba)2/RuPhos or another palladium source/phosphine-based ligand at variable temperature from 100 to 150 °C, for a period ranging from few hours to overnight.
• a suitable organic solvent such as dioxane or toluene or DMA
• an inorganic base such as K2PO4 or CS2CO3
• a suitable palladium catalytic system such as Pd(dba)2/RuPhos or another palladium source/phos
• a compound of formula (VII) or (VII)’ may be converted into a compound of formula (I) or (I)’, wherein Y is absent, by performing a nucleophilic aromatic substitution using a fluoride compound of formula (IX) or (IX)’, in a suitable organic solvent, such as DMSO, in the presence of an inorganic base, such as CS2CO3 or K2CO3, at a temperature variable from 80 to 110 °C, for a period ranging from few hours to overnight.
• a suitable organic solvent such as DMSO
• an inorganic base such as CS2CO3 or K2CO3
• a compound of formula (I)’ is an embodiment of a compound of formula (I).
• a compound of formula (II)’ or (III)’ or (IV)’ or (V)’ or (VI)’ or (VII)’ or (VIII)’ or (IX)’ or (X)’ is and embodiment of a compound of formula (II) or (III) or (IV) or (V) or (VI) or (VII) or (VIII) or (IX) or (X), respectively.
• a compound of formula (I) or (I)’ comprises a stereogenic center, which is the carbon atom of the pyrrolidine ring linked to the phenyl moiety.
• a compound of formula (I) or (I)’ prepared according to the approach depicted in Scheme 1 or 2, respectively, is provided as a racemic mixture.
• Intermediate compounds of formula (VI) or (VI)’ and of formula (VII) or (VII)’ are provided as racemic mixtures. Separation of the racemic mixtures may be achieved by chiral resolution methods, such as chiral purification. Both single enantiomers of a compound of formula (I) or (I)’, as well as its racemic mixture, are included in the scope of the present invention.
• intermediate compounds of formula (XV) may be obtained by starting from commercially available compounds of formula (XII).
• a compound of formula (XIII) may be prepared from a compound of formula (XII) through a palladium-catalyzed cross-coupling reaction.
• the reaction may be carried out by reacting a compound of formula (XII) with potassium trifluoro(vinyl)borate following the classical Suzuki protocol, in a suitable organic solvent, such as dioxane, in the presence of an inorganic base, such as CS2CO3, with an appropriate palladium catalytic system, such as Pd2(dppf)C12, at high temperature (around 100 °C) for few hours.
• 1,3 -dipolar cycloaddition may be carried out reacting the a, 13- unsaturated compound of formula (XIII) with a 1,3 -dipole or a suitable precursor, such as an azomethine ylide, for example N-benzyl-1 -methoxy -N-((trimethylsilyl) methyl)methanamine, under acid catalysis, such as by TFA, in a suitable solvent, such as dioxane.
• a suitable precursor such as an azomethine ylide, for example N-benzyl-1 -methoxy -N-((trimethylsilyl) methyl)methanamine
• the resulting compound of formula (XIV) may be converted into the debenzylated compound of formula (XV) by reduction under hydrogen atmosphere, typically 4 bar, in the presence of a suitable catalyst such as Pd/C in a suitable solvent such as, but not limited to, EtOH at a temperature ranging from RT to 60 °C, for few hours.
• Boc-protected compound of formula (XVI) may be prepared by reacting a compound of formula (XV) with di-tert-butyl dicarbonate, under basic conditions using an organic base, such as TEA, in an appropriate solvent, such as DCM.
• Compounds of formula (XIV), (XV) and (XVI) are provided as racemic mixtures (depicted in the Schemes with solid bonds).
• the stereogenic center which is the carbon atom of the pyrrolidine ring linked to the phenyl moiety, is indicated with a * in the compound of formula (XVI) in Scheme 3.
• Separation of the racemic mixture of the compounds of formula (XVI) is achieved by chiral resolution methods such as chiral purification, resulting in compounds of formula (XVI) as single enantiomers (not depicted in Scheme 3).
• Compounds of formula (XV) as single enantiomers may then be obtained from single enantiomers of compounds of formula (XVI) by removing the Boc protecting group in non-racemizing conditions such as acidic conditions, for instance by using an organic acid, such as TFA.
• compounds of formula (XVII) may be prepared by reacting a compound of formula (VII) with di-tert-butyl dicarbonate, under basic conditions by using an organic base, such as TEA, in an suitable solvent, such as DCM.
• organic base such as TEA
• suitable solvent such as DCM.
• Compounds of formula (XVII) are provided as racemic mixtures (depicted in the Schemes with solid bonds). Separation of the racemic mixture of the compounds of formula (XVII) is achieved by chiral resolution methods such as chiral purification, resulting in compounds of formula (XVII) as single enantiomers (not depicted in Scheme 3).
• a single enantiomer of an intermediate compound of formula (XV) may react with a carboxylic acid compound of formula (VIII) or with a fluoride compound of formula (IX) or with a bromide compound of formula (X), in the conditions described above, respectively, to obtain a compound of formula (XVIII) as single enantiomer.
• a transamidation reaction of a compound of formula (XVIII) with a suitable aryl amine of formula (XI) in the presence of a strong base, such as BuLi, LiHMDS or LDA, in an appropriate solvent, like THF provides a compound of formula (I), as single enantiomer.
• compounds of formula (I) as single enantiomers may be obtained from single enantiomers of compounds of formula (VII) reacting with a carboxylic acid compound of formula (VIII) or with a fluoride compound of formula (IX) or with a bromide compound of formula (X), in the conditions described referring to Scheme 1.
• a compound of formula (I) may be further reacted performing a conversion of a functional group into a different functional group thus obtaining another compound of formula (I).
• a nitrile, or cyano group may be converted into an amide group in a suitable organic solvent, such as DMSO, in the presence of a peroxide, such as hydrogen peroxide (see for instance the preparation of Example 17 from Example 4).
• a conversion of a functional group into a different functional group may be carried out as intermediate step, for instance in the preparation of a compound of formula (I) according to Scheme 5 and involving an intermediate compound of formula (XVII).
• a compound of formula (XVII) may undergo a transamidation reaction with a suitable aryl amine of formula (XI), thus providing a compound of formula (I).
• the present invention provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, comprising the step of: a) reacting a compound of formula (V) with N-benzyl-1 -methoxy -N-((trimethylsilyl)methyl)methanamine under acid catalysis in the presence of a solvent such as to obtain a compound of formula (VI) wherein R1 and R3 are as defined above, and converting the compound of formula (VI) into a compound of formula (I).
• the process further comprises the steps of: b) cleaving the benzyl group of the compound of formula (VI) such as to obtain a compound of formula (VII): by reduction under hydrogen atmosphere in the presence of a Pd catalyst; and c) reacting the compound of formula (VII) with a carboxylic acid compound of formula (VIII) or a fluoride compound of formula (IX) or a bromide compound of formula (X), such as to obtain a compound of formula (I).
• the present invention provides a compound of formula (VI) wherein R1 and R3 are as defined above.
• the invention further provides the use of the compound of formula (VI) as defined above in the preparation of a compound of formula (I).
• the present invention also provides a compound of formula (VII) wherein R1 and R3 are as defined above.
• the invention further provides the use of the compound of formula (VII) as defined above in the preparation of a compound of formula (I).
• the invention provides the use of the compound of formula (VI) and/or the compound of formula (VII) as defined above in the preparation of a compound of formula (I).
• the compounds of formula (I) of the present invention have surprisingly been found to effectively inhibit both receptor DDR1 and DDR2.
• the inhibition of receptors DDR1 and DDR2 may result in efficacious treatment of the diseases or condition wherein the DDR receptors are involved.
• the compounds of formula (I) of the present invention have an antagonist drug potency expressed as inhibition constant Ki on DDR1 and DDR2 between 60 and 25 nM, as shown in the present experimental part.
• the compounds of the present invention have a Ki on DDR1 and DDR2 between 25 and 10 nM. Even more preferably, the compounds of the present invention have a Ki on DDR1 and DDR2 lower than 10 nM.
• the present invention refers to a compound of formula (I) according to any of the embodiments disclosed above for use as a medicament.
• the invention refers to a compound of formula (I), and pharmaceutically acceptable salts thereof, for use in treating diseases, disorders, or conditions associated with dysregulation of DDR.
• the invention refers to the use of a compound of formula (I) as above described, and pharmaceutically acceptable salts thereof, in the preparation of a medicament for the treatment of disorders associated with dysregulation of DDR.
• the invention refers to a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the prevention and/or treatment of a disease, disorder or condition associated with DDR receptor mechanism.
• the present invention refers to a compound of formula (I) useful for the prevention and/or treatment of fibrosis and/or diseases, disorders, or conditions that involve fibrosis.
• fibrosis refers to conditions that are associated with the abnormal accumulation of cells and/or fibronectin and/or collagen and/or increased fibroblast recruitment and include, but are not limited to, fibrosis of individual organs or tissues such as the heart, kidney, liver, joints, lung, pleural tissue, peritoneal tissue, skin, cornea, retina, musculoskeletal and digestive tract.
• the compounds of formula (I) as above described are useful for the treatment and/or prevention of fibrosis such as pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), hepatic fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis.
• fibrosis such as pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), hepatic fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis.
• the compounds of formula (I) as above described are useful for the treatment of idiopathic pulmonary fibrosis (IPF).
• IPF idiopathic pulmonary fibrosis
• the invention also refers to a method for the prevention and/or treatment of disorders associated with DDR receptors mechanisms, said method comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) as above described.
• the invention refers to the use of a compound of formula (I) as above described for the treatment of disorders associated with DDR receptors mechanism.
• the invention refers to the use of a compound of formula (I) as above described in the preparation of a medicament for the treatment of disorders associated with DDR receptors mechanism.
• the invention refers to a method for the prevention and/or treatment of disorder or condition associated with dysregulation of DDR receptors 1 and 2, said method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of formula (I) as above described.
• the present invention refers to the use of a compound of formula (I) as above described for the treatment of a disease, disorder or condition associated with dysregulation of DDR receptors 1 and 2.
• safety and effective amount in reference to a compound of formula (I) or a pharmaceutically acceptable salt thereof or other pharmaceutically-active agent means an amount of the compound sufficient to treat the patient's condition but low enough to avoid serious side effects and that can nevertheless be routinely determined by the skilled artisan.
• the compounds of formula (I) may be administered once or according to a dosing regimen wherein a number of doses are administered at varying intervals of time for a given period of time. Typical daily dosages may vary depending upon the route of administration chosen.
• the present invention also refers to a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I) according to any of its embodiment in admixture with at least one or more pharmaceutically acceptable carrier or excipient.
• the invention refers to a pharmaceutical composition of compounds of formula (I) in admixture with one or more pharmaceutically acceptable carrier or excipient, for example those described in Remington’s Pharmaceutical Sciences Handbook, XVII Ed., Mack Pub., N.Y., U.S.A.
• Administration of the compounds of the invention and their pharmaceutical compositions may be accomplished according to patient needs, for example, orally, nasally, parenterally (subcutaneously, intravenously, intramuscularly, intrasternally and by infusion) and by inhalation.
• the compounds of the present invention are administered orally or by inhalation.
• the pharmaceutical composition comprising the compound of formula (I) is a solid oral dosage form such as tablets, gelcaps, capsules, caplets, granules, lozenges and bulk powders. In one embodiment, the pharmaceutical composition comprising the compound of formula (I) is a tablet.
• the compounds of the invention can be administered alone or combined with various pharmaceutically acceptable carriers, diluents (such as sucrose, mannitol, lactose, starches) and known excipients, including suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
• diluents such as sucrose, mannitol, lactose, starches
• excipients including suspending agents, solubilizers, buffering agents, binders, disintegrants, preservatives, colorants, flavorants, lubricants and the like.
• the pharmaceutical composition comprising a compound of formula (I) is a liquid oral dosage form such as aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
• a liquid oral dosage form such as aqueous and non-aqueous solutions, emulsions, suspensions, syrups, and elixirs.
• Such liquid dosage forms can also contain suitable known inert diluents such as water and suitable known excipients such as preservatives, wetting agents, sweeteners, flavorants, as well as agents for emulsifying and/or suspending the compounds of the invention.
• the pharmaceutical composition comprising the compound of formula (I) is an inhalable preparation such as inhalable powders, propellant-containing metering aerosols or propellant-free inhalable formulations.
• the powder may be filled in gelatine, plastic or other capsules, cartridges or blister packs or in a reservoir.
• a diluent or carrier chemically inert to the compounds of the invention e.g. lactose or any other additive suitable for improving the respirable fraction may be added to the powdered compounds of the invention.
• Inhalation aerosols containing propellant gas such as hydrofluoroalkanes may contain the compounds of the invention either in solution or in dispersed form.
• the propellant-driven formulations may also contain other ingredients such as co-solvents, stabilizers and optionally other excipients.
• the propellant-free inhalable formulations comprising the compounds of the invention may be in form of solutions or suspensions in an aqueous, alcoholic or hydroalcoholic medium and they may be delivered by jet or ultrasonic nebulizers known from the prior art or by soft-mist nebulizers.
• the compounds of the invention can be administered as the sole active agent or in combination with other pharmaceutical active ingredients.
• the dosages of the compounds of the invention depend upon a variety of factors including among others the particular disease to be treated, the severity of the symptoms, the route of administration and the like.
• the invention is also directed to a device comprising a pharmaceutical composition comprising a compound of Formula (I) according to the invention, in form of a single- or multi -dose dry powder inhaler or a metered dose inhaler.
• a “similar” or “analogous” procedure means that such a procedure may involve minor variations, for example reaction temperature, reagent/solvent amount, reaction time, work-up conditions or chromatographic purification conditions.
• TEA triethylamine
• CV Column Volumes
• DMF dimethylformamide
• DMA dimethylacetamide
• Et2O diethyl ether
• THF tetrahydrofuran
• DCM dichloromethane
• ACN acetonitrile
• MeOH methyl alcohol
• EtOH ethanol
• tBu tert-butyl
• EtOAc ethyl acetate
• Boc tert-butyloxycarbonyl
• rt/RT room temperature
• LC-MS Liquid Chromatography /Mass Spectrometry
• MW Microwave
• SCX solid cation exchange
• DMSO-d6 deuterated dimethyl sulfoxide
• SFC supercritical fluid chromatography
• CDC13 deuterated chloroform
• NMR nuclear magnetic resonance
• DIPEA diisopropylethylamine
• HCOOH formic acid
• TBTU O-(benzotriazol-l
• T H NMR spectra were recorded on Varian MR-400 spectrometer operating at 400 MHZ (proton frequency), equipped with: a self-shielded Z-gradient coil 5 mm IH/nX broadband probe head for reverse detection, deuterium digital lock channel unit, quadrature digital detection unit with transmitter offset frequency shift. Chemical shifts are reported as 6 values in ppm relative to tetramethyl silane (TMS) as an internal standard.
• TMS tetramethyl silane
• Method 1 Acquity CSH C18 column 50mm x 2.1mm 1.7pm, maintained at 40°C; Mobile Phase: Eluent B (MeCN/water 95:5 +0.05% HCOOH) in Eluent A (water/MeCN 95:5 +0.05% HCOOH) from 1% to 99.9% within 1.5 min. Flow rate: 1 mL/min. Wavelength: 210-400 nm DAD. UPLC + WatersTM PDA + WatersTM QDA.
• Method 2 Acquity CSH C18 column 50mm x 2.1mm 1.7pm, maintained at 40°C; Mobile Phase: Eluent B (MeCN/water 95:5 +0.05% HCOOH) in Eluent A (water/MeCN 95:5 +0.05% HCOOH) from 1% to 99.9% within 3.5 min. Flow rate: 1 mL/min. Wavelength: 210-400 nm DAD. UPLC + WatersTM PDA + WatersTM QDA.
• Method 3 WatersTM Acquity QSM, Acquity UPLC CSH C18 column 50mm x 2.1mm 1.7pm, maintained at 50°C; Mobile Phase: Eluent A (HCOONH4 0.025M pH 3), Eluent B (ACN+0.1% FA). Gradient mode: from 0 to 5.50 min. eluent B is increased from 20% to 80%, from 5.50 to 7.50 min. is kept at 80%, from 7.50 to 8 min. is decreased from 80% to 20%, and from 8 min. it is kept at 20% till the end at 10 min. Flow rate: 0.35 mL/min. Wavelength: 210-400 nm DAD. UPLC + WatersTM PDA + Xevo TQS MS instrument.
• Method 4 WatersTM Acquity QSM, Kinetex C8 column 100mm x 2.1mm 1.7pm, maintained at 55°C; Mobile Phase: Eluent A (HCOONH4 0.025M pH 3), Eluent B (ACN+0.1% FA). Gradient mode: from 0 to 3 min. eluent B is increased from 1% to 30%, from 3 to 6.50 min. is increased from 30% to 50%, from 6.50 to 7.50 min. is increased from 50% to 80%, from 7.50 to 8 min is kept at 80%, from 8 to 8.10 min. is decreased from 80% to 1% and from 8.10 it is kept at 1% till the end at 10 min. Flow rate: 0.5 mL/min. Wavelength: 210-400 nm PAD. UPLC + WatersTM PDA + Xevo TQS MS instrument.
• the diastereomeric separation of compounds was achieved by Supercritical Fluid Chromatography (SFC) using a WatersTM Thar Prep 100 preparative SFC system (P200 CO2 pump, 2545 modifier pump, 2998 UV/VIS detector, 2767 liquid handler with Stacked Injection Module).
• SFC Supercritical Fluid Chromatography
• Method 5 SFC-MS was performed on a Gilson Preparative LC system (Gilson Pump - 333; Gilson 151; Gilson Valvemate 6 position) using a Reprosil AMS (20mm x 250mm, 5pm) column with an isocratic run (20:80 MeOHUCh (0.2% v/v NH3), Flow Rate 50 mL/min, BPR 100 BarG, Detector Wavelength 210 nm, Injection Volume 1500 pL (213 mg), 40°C column temperature.
• Method 7 Acquity BEH C18 (2.1mm x 50mm, 1.7pm ) maintained at 60 °C; Flow Rate 1.0 mL/min; Detector Wavelength 220-300nm; Injection Volume 1.0 pL; Mobile Phase Eluent B MeCN Eluent A Water (0.1% v/v TFA) from 2% to 98% within 2 min. Flow rate: 1 mL/min. Wavelength: 220-300 nm.
• Method 8 Acquity UPLC BEH Shield RP18 column, 100 x 2.1mm, 1.72pm (Plus guard cartridge), maintained at 40 °C.
• Mobile phase MeCN in water + 10 nM ammonium bicarbonate from 5% to 95% within 5.6 min.
• Wavelength 210- 400 nm DAD.
• Method 10 SFC-MS was performed on a WatersTM/Thar SFC systems with WatersTM SQD using a LUX Cellulose-1 (20x250 mm, 5 pm) column with an isocratic run (50:50 isopropanol (NH4OH 0.1%):CO2), flow rate 100 mL/min, 120 bar, 40 °C column temperature, DAD wavelength 265 nm.
• Method 11 SFC-MS was performed on a Gilson Preparative LC system (Gilson Pump - 333; Gilson 151; Gilson Valvemate 6 position) using a Chiralcel OD-H (30mm x 250mm, 5pm) column with an isocratic run (10:90 MeOHUCh), flow rate 180 mL/min, BPR 120 BarG, detector wavelength 237 nm, injection volume 1500 pL (135 mg), 40 °C column temperature.
• Method 12 SFC-MS was performed on a Gilson Preparative LC system using a Lux Cl (4.6mm x 250mm, 5pm) column with a isocratic run (20:80 MeOH(0.2% v/v NHsjUCh), detector wavelength 210-400 nm, injection volume 1.0 mL, BPR 125 BarG, flow rate 4 mL/min, 40 °C column temperature.
• Method 13 WatersTM Acquity CSH UPLC column, 2.1x50mm, 1.7pm maintained at 40 °C. Mobile phase: MeCN (0.1% formic acid) in water (0.1% formic acid), from 3% to 99% within 1.5 min; flow rate: 1.0 ml/min; wavelength: 200-400 nm DAD. Acquity H- Class UPLC with PDA detector and QDa Mass Spectrometer.
• Method 14 Acquity BEH UPLC column, 2.1x50mm, 1.7pm, maintained at 40 °C. Mobile phase: MeCN (0.03% ammonia) in water (0.03% ammonia), from 8% to 97% within 1.5 min; flow rate: 0.8 ml/min; wavelength: 210-400 nm DAD. Acquity H-Class UPLC with PDA detector and QDa.
• IR and VCD were recorded at BioTools Inc. on a ChirallR w/ DualPEM spectrometer at rt.
• the PEMs were optimized for 1400 cm -1 , and a resolution of 4 cm- 1 was used throughout.
• solutions with concentration of 7.1 mg in lOOuL of CDCE were investigated using a 100 pm path-length cell equipped with BaF2 windows.
• the solution spectra were recorded for 24 hours per enantiomer. Because both enantiomers are available, baseline corrections were introduced using the spectrum of a virtual racemate.
• Example 5 preparation of 4-methyl-3-(l-(5-(2-morpholinoethoxy)pyridin-3- yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide
• Step 3 4-methyl-N-(3-(trifluoromethyl)phenyl)-3-vinylbenzamide (Intermediate 10)
• reaction mixture was filtered over a celite pad and desiccated under reduced pressure, the residual was dissolved in 200 mL of AcOEt and was washed with NH4CI (1x100 ml), NaHCCh (lx lOOmL) and brine (lx 150 mL). The organic layers were dried over MgSCL, filtered and the solvent was evaporated under reduced pressure.
• the crude was purified via FCC (gradient from 100:0 to 40:60 in 10 CV eluent A: n-Heptane eluent B: AcOEt), the appropriate fraction were collected and desiccated to afford title compound (8 g, 26.2 mmol, 71 %).
• Step 6 4-methyl-3-(l-(5-(2-morpholinoethoxy)pyridin-3-yl)pyrrolidin-3-yl)- N-(3-(trifluoromethyl)phenyl)benzamide (Example 5)
• Example 13 preparation of 3-(l-(5-bromopyridin-3-yl)pyrrolidin-3-yl)-4- methyl-N-(3-(trifluoromethyl)phenyl)benzamide
• Example 13 preparation of 3-(l-(5-bromopyridin-3-yl)pyrrolidin-3-yl)-4- methyl-N-(3-(trifluoromethyl)phenyl)benzamide
• Example 15 and Example 16 Preparation of (R)-4-methyl-3-(l-(pyridin-3- yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide and (S)-4-methyl-3-(l- (pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide
• Step 1 5-(3-(2-methyl-5-((3-(trifluoromethyl) phenyl) carbamoyl)phenyl) pyrrolidin-l-yl)nicotinamide
• the crude material was purified via FCC on a silica gel (DCM/MeOH from 100:7 to 10: 1) to provide the title product that was purified again on FCC (NH column 28 g, DCM/MeOH 95:5) to give title compound (9 mg, 0.019 mmol, 28.8 % yield).
• Example 47 preparation of (S)-3-(l-(6-((l-(2-methoxyethyl)-lH-pyrazol-4- yl)amino)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3- (trifluoromethyl)phenyl)benzamide
• Example 47 preparation of (S)-3-(l-(6-((l-(2-methoxyethyl)-lH-pyrazol-4- yl)amino)pyridin-3-yl)pyrrolidin-3-yl)-4-methyl-N-(3- (trifluoromethyl)phenyl)benzamide
• Example 51 preparation of (S)-3-(l-(2-acetamidopyrimidin-5-yl)pyrrolidin-3- yl)-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide
• Example 50 (40 mg, 0.091 mmol) was dissolved in DCM (3 ml) then DIPEA (0.047 ml, 0.272 mmol) and acetyl chloride (7.11 mg, 0.091 mmol) were added. The mixture was stirred at rt overnight.
• Example 52 preparation of (S)-4-methyl-3-(l-(5-(l-methyl-lH-pyrazol-4- yl)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide
• Example 52 preparation of (S)-4-methyl-3-(l-(5-(l-methyl-lH-pyrazol-4- yl)pyridin-3-yl)pyrrolidin-3-yl)-N-(3-(trifluoromethyl)phenyl)benzamide
• a vial was loaded with K3PO4 (211 mg, 0.993 mmol), Example 62 (167 mg, 0.331 mmol), l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (152 mg, 0.73 mmol), Pd-170 (11.15 mg, 0.017 mmol), THF (2 ml) and water (2.0 ml). Solution was backfilled with Ar and then solution was stirred for 1 h at 50 °C. The solution was filtered, diluted with EtOAc and washed with NaHCO, sat solution.
• Example 54 and Example 55 preparation of 4-(3-(2-methyl-5-((3- (trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-l-yl)picolinamide - first eluting and second eluting isomers
• Example 54 First eluting
• Example 55 (Second eluting)
• the isomers of racemic mixture of Example 53 (10 mg) were separated by chiral SFC. Combined fractions of single enantiomer were then evaporated to near dryness using a rotary evaporator, then in a vacuum oven, to afford the two single enantiomers.
• Second eluting isomer (1.0 mg, 2.10 pmol, 10 %).
• Example 56 preparation of (S)-5-(3-(2-methyl-5-((4-(morpholinomethyl)-3- (trifluoromethyl)phenyl)carbamoyl)phenyl)pyrrolidin-l-yl)nicotinamide
• a IL reactor was purged with nitrogen and charged with palladium/C 10 (50% wet) (21.88 g, 10.28 mmol). The system was purged once more with nitrogen and placed under vacuum. A solution of Intermediate 43 (133 g, 411 mmol) in EtOH (500 ml) was then charged. The solution was then placed under an atmosphere of hydrogen (4 bar) and warmed to 60 °C and stirred for 8 h. The reaction mixture was filtered through celite and concentrated, then the crude was dissolved in Et2O and extracted with HCL IN in quantitative yield.
• Example 58 was prepared following the procedure of Intermediate 49 starting from Intermediate 50 (126 mg, 0.25 mmol). After precipitation from water and washing with ethyl ether, the desired product was obtained (77 mg, 0.147 mmol, 59 % yield).
• Example 59 preparation of (S)-3-(l-(5-acetamidonicotinoyl)pyrrolidin-3-yl)- 4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide
• Example 59 preparation of (S)-3-(l-(5-acetamidonicotinoyl)pyrrolidin-3-yl)- 4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide
• Example 59 was prepared following procedure of Intermediate 3 starting from Intermediate 17 (100 mg, 0.287 mmol) and 5-acetamidonicotinic acid (130 mg, 0.722 mmol). The residue was purified via reverse phase FCC and charged over SCX column, washed with MeOH and eluted with methanolic ammonia to give the desired product (29.2 mg, 0.057 mmol, 20 % yield).
• Comparative newly synthesized compounds characterized by having an aziridinyl in place of a pyrrolidinyl ring (Cl) or a -CEb- linker between the pyrrolidinyl ring and group A (C2), were prepared as following:
• a solution of the ylide was prepared under nitrogen from trimethyl sulfoxonium iodide (48.1 mg, 0.219 mmol), sodium hydride (5.24 mg, 0.219 mmol), and dry DMSO (3 ml). With stirring, a solution of Intermediate 21 (69.8 mg, 0.182 mmol) in dry DMSO (3 ml) was added at RT, then the solution was stirred at rt for 1 h. and at 60°C for 2 h.
• DDR1 and DDR2 binding assays were performed using Life Technologies LanthaScreenTM Europium Kinase Binding assay. The compounds were incubated with 5 nM DDR1 (Carna Biosciences) or 5 nM DDR2 (Life Technologies) for 1 hour at rt in white 384-well OptiPlate (PerkinElmer), containing 20 nM or 10 nM Kinase Tracer 178 respectively and 2 nM Europium labelled anti-GST antibody (Life Technologies) in assay buffer (50 mM HEPES pH 7.5, 10 mM MgCI2, 1 mM EGTA and 0.01% BRIJ35).
• assay buffer 50 mM HEPES pH 7.5, 10 mM MgCI2, 1 mM EGTA and 0.01% BRIJ35.
• the compounds of Table 5 i.e. the compounds of the invention, show a good activity as antagonist of DDR1 and DDR2. Accordingly, the compounds of the invention can be effectively used for treating disease, disorder or condition associated with DDR receptors, such as fibrosis, e.g. pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), hepatic fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis.
• fibrosis e.g. pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), hepatic fibrosis, renal fibrosis, ocular fibrosis, cardiac fibrosis, arterial fibrosis and systemic sclerosis.
• fibrosis e.g. pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), hepatic fibrosis, renal fibrosis,
• the compounds of the present invention have a binding affinity for DDR1 and DDR2 receptors expressed as Ki lower than 60 nM, and for most of the compounds lower than 25 nM or even lower than 10 nM, whereas comparative Compound Cl has a binding affinity higher than 170 nM on DDR1 receptor, even of 571 for C2, and higher than 300 on DDR2 receptor for Cl, even of 764 for C2.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Ophthalmology & Optometry (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Gastroenterology & Hepatology (AREA)
• Urology & Nephrology (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (8)

Applications Claiming Priority (2)

Publications (1)

Family

ID=78516515

Family Applications (1)

Country Status (9)

Citations (1)

• 2022
  • 2022-10-17 WO PCT/EP2022/078767 patent/WO2023066834A1/en not_active Ceased
  • 2022-10-17 AU AU2022372296A patent/AU2022372296A1/en active Pending
  • 2022-10-17 JP JP2024523483A patent/JP2024540916A/ja active Pending
  • 2022-10-17 US US18/702,454 patent/US20240425482A1/en active Pending
  • 2022-10-17 EP EP22803220.7A patent/EP4419516A1/en active Pending
  • 2022-10-17 CA CA3235345A patent/CA3235345A1/en active Pending
  • 2022-10-17 MX MX2024004632A patent/MX2024004632A/es unknown
  • 2022-10-17 KR KR1020247016199A patent/KR20240093648A/ko active Pending
  • 2022-10-17 CN CN202280076310.4A patent/CN118284601A/zh active Pending

Patent Citations (1)

Non-Patent Citations (16)

Also Published As

Similar Documents

Legal Events